PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-4.59%
Cash & equivalents declining -4.59% while AGEN's grows 42.60%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
-40.54%
Short-term investments yoy growth below half of AGEN's 0.11%. Michael Burry might see potential liquidity risk. Investigate alternative capital uses or constraints.
-4.61%
Below half of AGEN's 42.60%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.92%
Below half of AGEN's 42.83%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
10.64%
0.75-0.9x AGEN's 12.62%. Bill Ackman questions if competitor invests more heavily in future capacity.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.58%
Below half of AGEN's -0.48%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Below half of AGEN's 34.70%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-12.14%
Less than half of AGEN's 16.11%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Less than half of AGEN's 0.00%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
≥ 1.5x AGEN's -23.27%. David Dodd sees stronger subscription/prepayment demand.
-34.95%
Exceeding 1.5x AGEN's -16.76%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-29.36%
Less than half of AGEN's 11.71%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.36%
Less than half of AGEN's 78.25%. David Dodd sees far fewer liability expansions relative to competitor.
3.53%
Above 1.5x AGEN's 0.46%. Michael Burry suspects heavy new equity expansion or dilution.
-3.88%
≥ 1.5x AGEN's -1.75%. David Dodd sees higher yoy retained profits than competitor.
-25.46%
Less than half of AGEN's -102.25%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.65%
Below half AGEN's -11.71%. Michael Burry sees potential underperformance in building shareholder capital.
-4.86%
Below half AGEN's 34.70%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-40.54%
Below half AGEN's 0.11%. Michael Burry suspects major underinvestment or forced divestment.
-100.00%
Less than half of AGEN's 868.72%. David Dodd sees less overall debt expansion vs. competitor.
4.24%
Less than half of AGEN's 31.03%. David Dodd sees better deleveraging or stronger cash buildup than competitor.